{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T04:03:36Z","timestamp":1784347416384,"version":"3.55.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:00:00Z","timestamp":1793232000000},"content-version":"am","delay-in-days":332,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000890","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","award":["RG-1904\\u201333,834"],"award-info":[{"award-number":["RG-1904\\u201333,834"]}],"id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["K12NS098482\\u201308"],"award-info":[{"award-number":["K12NS098482\\u201308"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["K23NS117883"],"award-info":[{"award-number":["K23NS117883"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020779","name":"Siegel Rare Neuroimmune Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020779","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.msard.2025.106810","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:13:24Z","timestamp":1761128004000},"page":"106810","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Significance of brain lesions associated with optic neuritis in pediatric myelin oligodendrocyte glycoprotein antibody-associated disease"],"prefix":"10.1016","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0426-4268","authenticated-orcid":false,"given":"Vivien X.","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiwen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Har","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Spagnolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melike","family":"Guryildirim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilana","family":"Kahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leigh","family":"Sepeta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias S.","family":"Sotirchos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra B.","family":"Kornbluh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106810_bib0001","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2023-332542","article-title":"Evolution of brain MRI lesions in paediatric myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and its relevance to disease course","author":"Abdel-mannan","year":"2023","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2025.106810_bib0002","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1474-4422(19)30488-0","article-title":"Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study","volume":"19","author":"Armangue","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106810_bib0003","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD Panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106810_bib0004","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejpn.2020.10.007","article-title":"E.U. paediatric MOG consortium consensus: part 4 \u2013 Outcome of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders","volume":"29","author":"Bruijstens","year":"2020","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.msard.2025.106810_bib0005","article-title":"E.U. paediatric MOG consortium consensus: part 1 \u2013 Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders","author":"Bruijstens","year":"2020","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.msard.2025.106810_bib0006","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209303","article-title":"Radiologic lag and brain MRI lesion dynamics during attacks in MOG antibody-associated disease","volume":"102","author":"Cacciaguerra","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106810_bib0007","doi-asserted-by":"crossref","first-page":"e1376","DOI":"10.1212\/WNL.0000000000207478","article-title":"Timing and predictors of T2-lesion resolution in patients with myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"101","author":"Cacciaguerra","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106810_bib0008","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.37833","article-title":"Frequency of new silent MRI lesions in myelin oligodendrocyte glycoprotein antibody disease and aquaporin-4 antibody neuromyelitis optica spectrum disorder","volume":"4","author":"Camera","year":"2021","journal-title":"JAMa Netw. Open."},{"key":"10.1016\/j.msard.2025.106810_bib0009","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000005560","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults","volume":"90","author":"Cobo-Calvo","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106810_bib0010","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1474-4422(20)30432-4","article-title":"Paediatric multiple sclerosis and antibody-associated demyelination: clinical, imaging, and biological considerations for diagnosis and care","volume":"20","author":"Fadda","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106810_bib0011","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ana.25957","article-title":"Silent new brain MRI lesions in children with MOG-antibody associated disease","volume":"89","author":"Fadda","year":"2021","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2025.106810_bib0012","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000207429","article-title":"Deviation from normative whole brain and deep gray matter growth in children with MOGAD, MS, and monophasic seronegative demyelination","volume":"101","author":"Fadda","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106810_bib0013","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1212\/WNL.0b013e3182a55f17","article-title":"Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children","volume":"81","author":"Friedman","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106810_bib0014","doi-asserted-by":"crossref","first-page":"e2172","DOI":"10.1212\/WNL.0000000000011827","article-title":"Association of white matter hyperintensity markers on MRI and long-term risk of mortality and ischemic stroke: the SMART-MR study","volume":"96","author":"Ghaznawi","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106810_bib0015","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3928\/1081-597X-19970701-16","article-title":"Proper method for calculating average visual acuity","volume":"13","author":"Holladay","year":"1997","journal-title":"J. Refract. Surg."},{"key":"10.1016\/j.msard.2025.106810_bib0016","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s12974-020-01825-1","article-title":"Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: results from 108 lumbar punctures in 80 pediatric patients","volume":"17","author":"Jarius","year":"2020","journal-title":"J. Neuroinflammat."},{"key":"10.1016\/j.msard.2025.106810_bib0017","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1038\/s41433-024-03108-y","article-title":"MOG antibody-associated optic neuritis","volume":"38","author":"Jeyakumar","year":"2024","journal-title":"Eye"},{"key":"10.1016\/j.msard.2025.106810_bib0018","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/brain\/aww350","article-title":"Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.msard.2025.106810_bib0019","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/brain\/aww350","article-title":"Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.msard.2025.106810_bib0020","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.msard.2025.106810_bib0021","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1177\/1352458513484547","article-title":"International pediatric multiple sclerosis study group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions","volume":"19","author":"Krupp","year":"2013","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2025.106810_bib0022","article-title":"Pediatric myelin oligodendrocyte glycoprotein antibody-associated disease in southern China: analysis of 93 cases","volume":"14","author":"Li","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2025.106810_bib0023","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/S1474-4422(22)00200-9","article-title":"Diagnosis and classification of optic neuritis","volume":"21","author":"Petzold","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106810_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102638","article-title":"Variability of cerebrospinal fluid findings by attack phenotype in myelin oligodendrocyte glycoprotein-IgG-associated disorder","volume":"47","author":"Sechi","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106810_bib0025","doi-asserted-by":"crossref","first-page":"e1097","DOI":"10.1212\/WNL.0000000000012467","article-title":"Comparison of MRI lesion evolution in different Central nervous system demyelinating disorders","volume":"97","author":"Sechi","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106810_bib0026","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/ene.14089","article-title":"Clinical, imaging and follow-up study of optic neuritis associated with myelin oligodendrocyte glycoprotein antibody: a multicentre study of 62 adult patients","volume":"27","author":"Shor","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2025.106810_bib0027","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2019.2940","article-title":"Serial anti-myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes","volume":"77","author":"Waters","year":"2020","journal-title":"JAMa Neurol."},{"key":"10.1016\/j.msard.2025.106810_bib0028","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jns.2007.09.025","article-title":"Effect of intravenous methylprednisolone on the number, size and confluence of plaques in relapsing-remitting multiple sclerosis","volume":"267","author":"Zivadinov","year":"2008","journal-title":"J. Neurol. Sci."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825005528?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825005528?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T03:33:00Z","timestamp":1784345580000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825005528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":28,"alternative-id":["S2211034825005528"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106810","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Significance of brain lesions associated with optic neuritis in pediatric myelin oligodendrocyte glycoprotein antibody-associated disease","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106810","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106810"}}